Filing Details

Accession Number:
0001731122-23-001246
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-30 20:00:21
Reporting Period:
2023-06-28
Accepted Time:
2023-06-30 20:00:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1314052 Anavex Life Sciences Corp. AVXL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1196573 U Christopher Missling 630 5Th Avenue
20Th Floor
New York NY 10111
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-28 268,000 $1.60 1,286,210 No 4 M Direct
Common Stock Disposition 2023-06-28 268,000 $7.98 1,018,210 No 4 S Direct
Common Stock Acquisiton 2023-06-29 232,000 $1.60 1,250,210 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-06-28 268,000 $0.00 268,000 $1.60
Common Stock Stock Option (Right to Buy) Disposition 2023-06-29 232,000 $0.00 232,000 $1.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
232,000 2013-07-05 2023-07-05 No 4 M Direct
0 2013-07-05 2023-07-05 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.